A Oxford-based health tech startup that has its United States headquarters in Houston has announced the close of its series A round of funding.
Optellum, which has created a breakthrough AI platform to diagnose and treat early-stage lung cancer, has raised $14 million in a series A funding round. The round was led by United Kingdom-based Mercia, with additional investors California-based Intuitive Ventures and New York-based Black Opal Ventures. Existing investors, including St John’s College in the University of Oxford, IQ Capital, and the family office of Sir Martin & Lady Audrey Wood, also participated in the round, per a news release.
“Lung cancer is an urgent public health crisis and Optellum’s groundbreaking approach utilizing AI to…